Navigation Links
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Date:5/17/2009

Positive data from subgroup analysis presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland

SAN DIEGO, May 17 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator Thomas J. Louie, M.D. for the first time in an oral presentation at the 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Helsinki, Finland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Dr. Louie presented the positive top-line results that the Company had previously announced in November 2008. The trial met its primary endpoint with fidaxomicin achieving clinical cure compared to Vancocin(R). In addition, patients treated with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure (cure with no recurrence within four weeks) compared to Vancocin (p=0.006).

"This study showed that fidaxomicin is as effective as vancomycin for treatment of C. Difficile diarrhea, including treatment of infection by the hyper virulent NAP1/ribotype 027 outbreak strain. Moreover, compared to vancomycin, recurrence of CDI is significantly less likely to occur following fidaxomicin therapy. Combining cure of CDI and freedom from recurrence, fidaxomicin is superior to vancomycin as treatment for this serious and common cause of infectious diarrhea," said Thomas J. Louie, M.D., Medical Director, Infection Prevention and Control for the Calgary Health R
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...irstCall/--AmericanScientificResourcesInc.(PinkShe...haveopenedaregionalmarketingandproductionmanagemen...urealocationabroad,providinganessentialgatewayfort...andsafetyproductsforchildrenandadultstobedistribut...ryinthestateofOhiowheretheywillalsobeabletodosubco...
(Date:11/25/2009)...5/PRNewswire/-- FromNovember16-18,Phonak,theleadin...dthesecondeditionoftheHearingCareforAdultsConferen...heconferencebroughttogetherleadingexpertsinagingan...nswhoworkeverydaywitholderpeoplewithhearinglossfor...researchandtrendsinhearingcareforolderpeople. ,...
(Date:11/25/2009)...swire/--AMPACFineChemicalsLLC(AFC),asubsidiaryofAm...daythatitreceivedtheEnvironmentalResponsibilityand...alSummit,sponsoredbytheCaliforniaManufacturersandT...talAssociation(IEA)andtheChemicalIndustryCouncilof...giousawardavailablefromallthreeorganizationsandgai...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Dr Christopher Olivia Appointed to Foundation Radiology Group Board of Directors 52779 1Dr Christopher Olivia Appointed to Foundation Radiology Group Board of Directors 52779 2Dr Christopher Olivia Appointed to Foundation Radiology Group Board of Directors 52779 3Diplomat Specialty Pharmacy Receives Regional Good Neighbor Pharmacy Of The Year Award 52775 1Diplomat Specialty Pharmacy Receives Regional Good Neighbor Pharmacy Of The Year Award 52775 2PharmAthene Inc Announces 2419 3 Million Private Placement of Convertible Notes and Common Stock Warrants 52772 1PharmAthene Inc Announces 2419 3 Million Private Placement of Convertible Notes and Common Stock Warrants 52772 2PharmAthene Inc Announces 2419 3 Million Private Placement of Convertible Notes and Common Stock Warrants 52772 3PharmAthene Inc Announces 2419 3 Million Private Placement of Convertible Notes and Common Stock Warrants 52772 4
...he Treatment of Inflammatory ...Payment from Partner GlaxoSmithKline, MOUNTAIN VI...unced the initiation of a Phase I clinical trial o...e compound designed to specifically,target the CCR...ammatory,diseases such as rheumatoid arthritis. Wi...
...i Corporation (,Iomai,) in a, fully recommended sh...ai,s common stock representing a fully diluted e...llion (EUR 122 million). Acquisition to be, accomp...imately 41 percent of Iomai,s current shares outs...ly 1.7 million Intercell shares (representing appr...
Other Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11
(Date:11/25/2009)...swire/--TheAmericanAssociationforHomecareendorsest...hisdesignedtosubstantiallyimprovetoolsandresources...ucedbySen.GeorgeLeMieux(R-Fla.). ,, TheLeMieuxb...forHomecareoutlinedinits13-pointanti-fraudactionpl....Thoseprovisionsincludecallingforreal-timeauditsan...
(Date:11/25/2009)...d into the body on a carefully engineered, fingern...minate tumors in mammals, scientists report this w... . , The new approach, pioneered by bioengineers...stic disks impregnated with tumor-specific antigen...mmalian immune system to attack tumors. The new pa...
(Date:11/25/2009)...r in children with autism and related conditions c...medication combined with a structured training pro...earchers and their colleagues. , Published in t...ican Academy of Child and Adolescent Psychiatry , ...of Mental Health (NIMH) Research Units on Pediatri...
(Date:11/25/2009)...ed parts of speech colored perception of sounds ,... People can "hear" not only with their ears, but a...act, sensations on the skin designed to mimic cert...r sounds better, the Canadian scientists found. ,...ld use tactile information in this way," said Brya...
(Date:11/25/2009)...to include cost-effective, sustainable distance tr...essionals in developing world. , ...- Elluminate, Inc. , the leader in web, audio, v... 21st century teaching, learning, and collaboratio...ive was awarded iNACOL,s first-ever Outstanding a...
Breaking Medicine News(10 mins):Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5
...pment of cancer. Cells without this protein are us...ity would either kill a cell or keep it from growi...h a way that they are able to multiply creating tu...// E2F3 is part of a family of proteins called tra...
...se electrocardiograph tests should be the first-li... patients with chest pain. Even though negative fi...ings could not distinguish levels of risk. The res...inical or exercise electrocardiography.// They com...
...p to 10, authorities are not confident about the g...wn a far higher recovery rate than the rest of the... medical care provided to SARS patients. Even what...tist at the National Institute of Communicable Dis...
...everal countries are forecast to shrink in the sec...s, from Filipina maids to Indonesian laborers and ...ommerce in the region, sending home in excess of $...irectly improving standards of living// and boosti...
...dian clinics where staffs worried about catching t...vernment hospital. Private medical centre closed t...ARS infected patients. The patients include a brid...e quarantined later to check if they developed sym...
...ay probably be small if the trip isn't to Asia. Pu...ently known about the virus. However people can be... strong filters against viruses. There have even b... filters to screen out spores, bacteria and viruse...
Other Medicine News:
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: